Similar articles

• Promises and pitfalls of anti-angiogenic therapy in clinical trials.

  McCarty MF, Liu W, Fan F, Parikh A, Reimuth N, Stoeltzing O, Ellis LM. McCarty MF, et al. Trends Mol Med. 2003 Feb;9(2):53-8. doi: 10.1016/s1471-4914(03)00002-9. Trends Mol Med. 2003. PMID: 12615038 Review.
• Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

  Ferrara N. Ferrara N. Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4. doi: 10.1053/sonc.2002.37264. Semin Oncol. 2002. PMID: 12516033 Review.
• Anticancer therapy with angiogenesis inhibitors.

  Ghilardi C, Bani MR, Giavazzi R. Ghilardi C, et al. Tumori. 2001 Nov-Dec;87(6):S14-6. Tumori. 2001. PMID: 11989610 Review. No abstract available.
• Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.

  Sepp-Lorenzino L, Thomas KA. Sepp-Lorenzino L, et al. Expert Opin Investig Drugs. 2002 Oct;11(10):1447-65. doi: 10.1517/13543784.11.10.1447. Expert Opin Investig Drugs. 2002. PMID: 12387705 Review.
• Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

  Jain RK. Jain RK. Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. doi: 10.1053/sonc.2002.37265. Semin Oncol. 2002. PMID: 12516032 Review.